DEFA14A filed Jun 4, 2026 at 16:24 ET
Pacira BioSciences issued a DEFA14A press release reminding stockholders to vote FOR management's three director nominees (Christopher Christie, Samit Hirawat, MD, Thomas Wiggans) on the BLUE proxy card at the June 9, 2026 annual meeting, and AGAINST all three nominees from activist investor DOMA Perpetual Capital Management. The filing highlights record 2025 financial results, Q1 2026 revenue growth across all commercial products (EXPAREL +5%, ZILRETTA +15%, iovera +21% YoY), and endorsements from all three leading proxy advisory firms (ISS, Glass Lewis, Egan-Jones) supporting management's slate.